Successful Consolidation/Maintenance Therapy with Single Agent Ibrutinib for Primary CNS Lymphoma after Initial Induction Therapy
Primary central nervous system lymphoma (PCNSL) is a rare and aggressive disease that originates from lymphocytes and develops in the central nervous system. There is no standard consolidation/maintenance therapy for PCNSL. While there exists a variety of options, the high chance of inferior outcome...
Saved in:
Main Authors: | Steven Du (Author), Daniela Bota (Author), Xiao-Tang Kong (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CNS-invasive aspergillosis following ibrutinib therapy
by: Matthew Kurian, et al.
Published: (2022) -
Mantle Cell Lymphoma: Effectiveness of Maintenance Ibrutinib - Case Report
by: Danuta Krasowska, et al.
Published: (2020) -
Multifocal periungual granulation tissue related to ibrutinib therapy
by: Aatman Shah, MD, et al.
Published: (2020) -
Cost-effectiveness Analysis of Rituximab Maintenance Treatment in Patients With Follicular Lymphoma who Respond to First Line Induction Therapy in Portugal
by: Susana Carvalho, et al.
Published: (2016) -
Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review
by: Gaurav Nepal, et al.
Published: (2022)